Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Noah Labs has developed a CE-marked Class IIa telemonitoring platform ("Ark") that integrates with external biosensors to enable early detection of cardiac decompensation in heart failure patients. Their proprietary AI algorithm ("Vox") analyzes multimodal data—including voice—to predict deterioration up to 14 days before standard methods. The solution is being validated in clinical trials at leading institutions such as Charité Berlin, Mayo Clinic USA, University Medical Center Maastricht, and Clinic Barcelona. Early results indicate improved early warning for cardiac events and reduced hospitalization rates.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Noah Labs.